Amphastar (AMPH) Q1 2026 Earnings Transcript

Amphastar Pharmaceuticals reported Q1 net revenue of $171.2 million, slightly above last year, but net income fell to $6.4 million from $25.3 million as gross margin compressed despite a 71% margin and a 33% increase in R&D spending. Growth was driven by new launches and core products, especially other finished pharmaceutical products up 34% and the newly launched ipratropium bromide inhalation product, while Vaxini fell 15% and glucagon plunged 56% on pricing and competitive pressure. Management cut Vaxini revenue expectations to flat-to-low-single-digit growth, maintained unit growth guidance, and noted a $29.5 million share repurchase and 2027 pipeline milestones still on track.

Analysis

The key read-through is that the quarter is less about a demand problem than a channel economics problem: Amphastar is still selling more units in the right places, but net realization is being compressed by rebate/340B leakage and mix rotation away from the highest-margin legacy products. That creates a very different earnings trajectory than a simple top-line miss — if management can actually audit duplicate discounts and hold the May price increase, the earnings rate of change can inflect faster than the reported revenue line suggests.

The more interesting second-order effect is competitive: the newly launched inhaled ipratropium looks like a temporary monopoly window, and those windows matter disproportionately for a company with a relatively small absolute revenue base. If the product ramps without immediate generic response, it can offset erosion in glucagon and help fund R&D internally, which in turn reduces financing risk and supports buybacks; that is a compounding mechanism, not just a one-quarter bump. The flip side is that once management starts leaning on one-off launch upside to offset base-business decay, the market usually starts valuing the stock on sustainability, not growth headlines.

The biggest underappreciated risk is that the pricing issue may not fully reverse even after the third-party review, because 340B/channel mix problems often migrate rather than disappear. So the stock can work tactically if investors believe in a Q2/Q3 margin recovery, but the durable bull case needs evidence that launch contributions and biosimilar timelines are real enough to replace the erosion in legacy franchises. The contrarian view is that consensus may be underestimating the value of the U.S. mix shift and the launch exclusivity window, while overestimating how quickly legacy price pressure normalizes.

Key Decisions for Investors

• Go long AMPH on a 3-6 month horizon only if you expect the May price increase and 340B review to show up in Q2 gross margin; upside is a re-rating on margin recovery, but the risk is that pricing leakage persists and the stock stays range-bound.
• Pair trade: long AMPH / short a basket of higher-multiple specialty pharma names with no near-term launch catalyst; the trade is attractive if investors rotate toward self-funded growth and buyback support rather than story stock duration.
• Buy AMPH January 2027 call spreads rather than outright equity if you want exposure to the 2027 biosimilar optionality; this caps downside if legacy erosion worsens while preserving upside if the pipeline and new launches re-rate the multiple.
• Take profits on any post-earnings strength unless Q2 commentary confirms stabilization in Vaxini net pricing and continued traction in ipratropium; the near-term asymmetry is better after proof points than on the initial launch headline.
• Avoid shorting AMPH aggressively here: the combination of buybacks, operating cash flow, and a temporary exclusivity window creates squeeze risk over the next 1-2 quarters if the market begins to price in a cleaner margin inflection.